Sionna Therapeutics, Inc. (SION) Receives a Rating Update from a Top Analyst
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Ritu Baral maintained a Buy rating on Sionna Therapeutics (SION) with a $49.41 price target on July 17, matching the stock's recent close. The broader market consensus for SION is a Moderate Buy with an average price target of $51.71.
TD Cowen analyst Ritu Baral maintained a Buy rating on Sionna Therapeutics, Inc. on July 17 and set a price target of $49.41. The company’s shares closed last Friday at $49.41.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Baral covers the Healthcare sector, focusing on stocks such as Insmed, Praxis Precision Medicines, and Atai Beckley N.V.. According to TipRanks, Baral has an average return of 46.0% and a 56.77% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sionna Therapeutics, Inc. with a $51.71 average price target.